Background: Large-scale prospective data are needed to determine whether associations between lipoprotein(a) (Lp[a]) and coronary heart disease (CHD) risk are independent of established risk factors, to characterize the shape of this relationship, and to quantify associations in relevant subgroups.
L

IPOPROTEIN(A) (LP[A]) IS
A low-density lipoproteinlike particle synthesized by the liver that consists of an apolipoprotein B molecule covalently linked to a very large glycoprotein known as apolipoprotein(a) (Apo[a]). 1, 2 Several epidemiologic studies have assessed the association between circulating Lp(a) levels and cardiovascular diseases. By 2000, there were 18 population-based prospective studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] that had reported on Lp(a) levels and coronary heart disease (CHD) risk, with most, but not all, reporting positive associations. Few studies, however, have been adequately powered to examine potentially important aspects of the association, such as the shape of the Lp(a)-CHD relationship and the size of relative risks in clinically relevant subgroups (such as in men and women or at different levels of established risk factors). A previous review 21 suggested a moderately strong overall association between Lp(a) levels and CHD risk, but because it analyzed only published data (rather than primary data) it did not address the uncertainties described in the preceding sentences. Furthermore, data on within-person variability are needed to help assess the long-term relevance of Lp(a) to CHD, but only 1 previous study 22 has reported on it using a small subset of individuals.
We report new primary data on the largest single study of Lp(a) concentrations and CHD thus far, involving 2047 patients with either first-ever nonfatal myocardial infarction or coronary death and 3921 control subjects "nested" within a prospective population-based cohort of 18 569 participants. As recommended by an expert panel, 23 we used an assay system that is not sensitive to Apo(a) isoform heterogeneity. Paired measurements were performed approximately 12 years apart in 372 participants to help quantify within-person variability in Lp(a) levels. We also report an updated review of previous prospective studies to help assess the comparability of associations of Lp(a) level with CHD risk reported in studies involving different blood handling, storage, and assay methods, particularly with assays affected by the variable affinity of antibodies to particular Apo(a) isoforms. 24, 25 The focus of the present report is on whether there is likely to be an etiologic association between Lp(a) levels and CHD (rather than the separate issue of risk prediction).
METHODS
STUDY POPULATION
The Reykjavik Study, initiated in 1967, has been described in detail elsewhere. 26 All men born between January 1, 1907, and December 31, 1934 , and all women born between January 1, 1908, and December 31, 1935 , who were residents of Reykjavik and its adjacent communities on December 1, 1966 , were identified in the national population register and were invited to participate in the study. Five stages of recruitment, between 1967 and 1991, yielded 8888 male and 9681 female participants with no history of myocardial infarction (72% response rate). Nurses administered questionnaires, performed physical measurements, recorded electrocardiograms, and collected fasting venous blood samples. Serum was stored at −20°C until assay. All the participants were monitored by central registries for the occurrence of major cardiovascular morbidity (based on MONICA [Monitoring Trends and Determinants in Cardiovascular Disease] criteria) or cause-specific mortality (based on a death certificate with International Classification of Diseases, Ninth Revision codes 410-414), with loss to follow-up of only approximately 0.6% to date. A total of 2459 men and women recorded either nonfatal myocardial infarction or coronary death between study entry and the censoring date. One or 2 controls were frequency matched to cases by calendar year of recruitment, sex, and age (in 5-year age bands) from among all participants who did not develop CHD during followup, giving a total of 3969 controls. Because of random nonavailability of serum samples, the present study is restricted to 2418 incident CHD cases and 3921 controls with available Lp(a) measurements. The study protocol was approved by the National Bioethics Committee and the Data Protection Commission of Iceland. All the participants gave informed consent.
LABORATORY METHODS
Levels of Lp(a) were measured in serum samples by laboratory staff unaware of participants' disease status using an enzyme immunoassay (ELITEST Lp [a] ) and an assay standard (both from HYPHEN BioMed, Paris, France). This enzymelinked immunosorbent assay-based system, which uses a monoclonal anti-Lp(a) antibody for capture and a polyclonal antiApo(B) antibody for detection, is not affected by Apo(a) isoform variation. The intra-assay and interassay coefficients of variation were 4.2% and 4.7%, respectively. The Lp(a) measurements were made in the 372 participants who provided paired samples at a mean interval of approximately 12 years. Lipid, biochemical, and hematologic measurements have been described previously. 26, 27 
STATISTICAL ANALYSES
To minimize any impact of preexisting disease, principal analyses were restricted to the 2047 patients and 3921 controls without evidence of CHD or stroke at the baseline examination (ie, participants with electrocardiographic abnormalities or a history of myocardial infarction, angina, or stroke were excluded from the main analyses, although they were retained in subsidiary analyses). The Lp(a) values were natural log transformed to achieve an approximately symmetrical distribution. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), progressively adjusted for possible confounding factors (Stata 9.2; StataCorp LP, College Station, Texas). The shape of the association between Lp(a) levels and CHD risk was investigated using groups defined by fifths of the baseline values of Lp(a) in controls; the corresponding 95% CIs were estimated from floated variances that reflect the amount of information underlying each group (including the reference group). 28 Subgroup analyses by sex, smoking habits, systolic and diastolic blood pressure (BP), concentrations of serum lipids and C-reactive protein, and type of CHD outcome were also prespecified. To quantify withinperson variability in levels of Lp(a) (and in other markers), regression dilution ratios were estimated from the available paired measurements by regressing repeated measures on baseline values. Regression dilution ratios for variables with skewed distributions (ie, Lp[a], C-reactive protein, and triglycerides) were calculated on the log scale. 29 An updated meta-analysis was conducted of prospective studies published before December 1, 2006, with more than 1 year of follow-up in essentially general populations (ie, in cohorts not selected on the basis of preexisting disease). 30 The analysis was restricted to nonfatal myocardial infarction or coronary death. To reduce potential biases, all the analyses involved only within-study comparisons (ie, Abbreviations: CHD, coronary heart disease; CI, confidence interval; Lp(a), lipoprotein(a); OR, odds ratio. a Individuals with evidence of electrocardiographic abnormalities, previous myocardial infarction, or a history of angina at the baseline survey were excluded from analyses.
b Cutoff points for the bottom and top thirds of Lp(a) levels were 42 and 149 mg/L, respectively (to convert to micromoles per liter, multiply by 0.0357). The adjusted OR (95% CI) for individuals in the middle vs bottom third of baseline Lp(a) distribution was 1.21 (1.04-1.40) and that for those in the top vs middle third was 1.32 (1.15-1.52) (adjusted for age, sex, period, smoking status, and other established CHD risk factors). The adjusted OR (95% CI) for a 1-log SD increase in baseline Lp(a) levels was 1.23 (1.16-1.31) (adjusted for established risk factors as previously). The SD for baseline log e Lp(a) values was 1.70 log mg/L; therefore, a 1-SD increase in log e Lp(a) corresponds to multiplying Lp(a) levels by a factor of 5.5 (since e 1.70 = 5.5). The OR (95% CI) with all incident CHD cases included (ie, also including those with evidence of coronary disease at baseline) was 1.62 (1.40-1.86) for individuals in the top vs bottom third of baseline Lp(a) distribution (adjusted for established CHD risk factors as previously). WWW.ARCHINTERNMED.COM 600 cases and controls were directly compared only within each cohort). Data were combined using a random-effects model. Heterogeneity was assessed using standard 2 tests and the I 2 statistic. 31 In the few studies that reported only 3 or 4 categories of Lp(a), rather than continuous values (owing to the use of semiquantitative assays based on reading of electrophoretic bands 6, 11 ), the highest category was taken to correspond to the upper third and the lowest category to the bottom third of baseline Lp(a) values. For studies reporting associations for men and women separately, a pooled estimate was calculated, weighted by their contributing proportions. Analyses involved formal tests of interaction to assess the effect of the following prespecified study characteristics: year of publication, study size, geographic location, ethnicity, sample storage features (ie, temperature and type), and features related to Lp(a) assay methods used.
RESULTS
As expected, levels of established cardiovascular risk factors at the baseline examination were higher in patients with CHD than in controls ( Table 1) . Baseline logLp(a) levels were higher in patients with CHD than in controls and were weakly, although significantly, correlated with levels of total cholesterol (r=0.12; 95% CI, 0.09 to 0.15), log triglycerides (r = −0.12; 95% CI, −0.16 to −0.09), tissue plasminogen activator antigen (r=−0.09; 95% CI, −0.12 to −0.06), serum creatinine (r=−0.05; 95% CI, −0.08 to −0.02), and uric acid (r=−0.06; 95% CI, −0.09 to −0.02). There were no significant correlations between baseline log-Lp(a) levels and various established and emerging cardiovascular risk factors, such as age, sex, BP, body mass index, C-reactive protein, and albumin (data available on request). In the 372 participants who provided paired measurements at baseline and approximately12 years later, the regression dilution ratios were as follows: 0.92 (95% CI, 0.85-0.99) for log Lp(a), 0.54 (95% CI, 0.44-0.64) for log C-reactive protein, 0.57 (95% CI, 0.48-0.66) for log triglycerides, 0.55 (95% CI, 0.45-0.65) for von Willebrand factor, 0.59 (95% CI, 0.51-0.67) for total cholesterol, and 0.65 (95% CI, 0.54-0.77) for systolic BP ( Figure 1A) . Data on high-density lipoprotein cholesterol were unavailable.
In a comparison of individuals with baseline Lp(a) values in the top third vs the bottom third, the OR for CHD was 1.61 (95% CI, 1.41-1.84) after adjustment for age, sex, and calendar year of recruitment ( Table 2) . This OR changed little after further adjustment for several established cardiovascular risk factors (ie, smoking status, BP, total cholesterol, triglycerides, body mass index, and diabetes mellitus) and inflammatory markers (eg, C-reactive protein). Subsidiary analyses yielded adjusted ORs for CHD of 1.77 (95% CI, 1.57-1.99) in a comparison of extreme fifths and of 1.23 (95% CI, 1.16-1.31) for log-Lp(a) levels higher by 1 SD. Figure 1B shows that, in comparisons of several established and emerging markers in the same patients and controls, ORs for CHD with Lp(a) were smaller than those with total cholesterol. Figure 2 shows that the ORs for CHD increased continuously with increasing Lp(a) levels (PϽ.001, test for linear trend), although further work is needed to determine whether a straight line or a curvilinear line better describes the association. Figure 3A suggests that the association of Lp(a) levels with CHD risk did not vary materially in a range of subgroups based on individual characteristics, notably, sex, lipid concentrations, C-reactive protein, and fatal vs nonfatal CHD outcome (PϾ .10 for each test of heterogeneity). Table 3 and Table 4 summarize the characteristics of 31 prospective studies of Lp(a), the first of which was published in 1990, 19 with 14 studies reported since the publication of a meta-analysis in 2000. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [43] [44] [45] [46] All the studies were based in continental North America or in Western Europe except 1. 36 Most studies identified participants in population registers (eg, general practitioner lists or electoral rolls) or in occupational settings, involved middle-aged men of white European continental ancestry, and reported on incident myocardial infarction and coronary death outcomes. The interval between sample collection and assay performance varied from a few hours to approximately 20 years. Eighteen studies* measured Lp(a) levels in plasma and 13 studies (including the present study) † in serum, with measurements generally performed in samples thawed after long-term storage at temperatures of −70°C or colder, whereas few studies conducted assays in samples stored at temperatures ranging from −70°C to −20°C 12, 17, 18, 39, 41 or in freshly collected samples. 6, 10, 35 Apart from 6 studies 6, 8, 10, 11, 32, 35 that * References 7, 8, 11, 14, 15, 17, [32] [33] [34] [35] [39] [40] [41] [42] 44, [46] [47] [48] 6, 10, 12, 13, 18, 19, 36, 37, 43, 45, 46. used in-house Lp(a) assays, most of the studies used commercially available immunoassays. Assay results were generally reported as mass per volume, although 1 study 8 used an analytical method that measured molarity, and 2 studies 6,11 used semiquantitative assay methods. Detailed information on assay methods (such as the exact antibodies used and the existence of sensitivity to Lp[a] isoforms) was reported in only a subset of studies (Table 4) . Reported mean or median levels of Lp(a) in controls varied substantially across studies, ranging from approximately 10 to 300 mg/L (to convert to micromoles per liter, multiply by 0.0357) (although, as in the present study, most were 50-200 mg/L). All but 3 studies 10,32,45 reported adjustment of CHD ORs for at least age, sex, smoking status, BP, and lipid concentrations. Using only withinstudy comparisons, a combined analysis of published data from these studies (including the present study) involving a total of 9870 incident CHD cases yielded an adjusted OR of 1.45 (95% CI, 1.32-1.58) for individuals in the top third of the baseline Lp(a) distribution compared with those in the bottom third (Figure 4) . There was moderate heterogeneity among these studies ( 2 30 =52.6; P=.007; I 2 = 43% [95% CI, 12%-63%]), some of which was explained by period of publication (P=.004) and sample type (P = .003) but only a small part by other characteristics prespecified for investigation, notably, study size, sample storage characteristics, and Lp(a) assay isoform sensitivity or standard used (PϾ.10 for each characteristic) ( Figure 3B) . A funnel plot did not show an excess of extreme findings in smaller studies (Egger test P =.23) (data available on request).
32-47
COMMENT
We demonstrated that the decade-to-decade consistency of Lp(a) levels in adults is very high, considerably higher than that of BP, serum lipid levels, and Creactive protein concentration. Contrary to previous reports of no associations with CHD risk 4, 15, 45 or of effects at only very high Lp(a) levels, the present, much largerscale data indicate an approximately continuous relationship. In direct comparisons with several established and emerging markers, we showed that the OR for CHD with elevated Lp(a) levels is comparable to those with systolic BP and at least as strong as those with Creactive protein 27 and triglycerides. 49 However, whereas ORs with C-reactive protein 27 or triglycerides 49 diabetes mellitus, and body mass index), the OR with Lp(a) changed very little after such adjustment. This observation suggests that Lp(a) levels are associated with CHD risk independent of such factors. We showed that ORs for CHD with Lp(a) levels were similar in a range of clinically relevant subgroups, such as in men and women, or at different levels of established risk factors and under different blood handling, storage, and assay conditions. These findings may have several implications for the development of CHD prevention strategies. First, the demonstration of high consistency of Lp(a) levels within individuals across many years emphasizes the lipoprotein's lack of substantial correlation with lifestyle characteristics or with several established risk factors (as shown in the cross-sectional analyses) and underscores the strong influence of the LPA locus on Lp(a) levels. 50 Such high reproducibility suggests the simplifying conclusion that, unlike many other biomarkers, most of the effect of Lp(a) on CHD risk can be assessed using a single measurement. Second, by reliably showing that there are progressively higher ORs for CHD with increasing Lp(a) levels, we have renewed interest in existing and new strategies to modify Lp(a) levels. The demonstration of moderately strong ORs for CHD with elevated Lp(a) levels independent of several established risk factors should en- courage studies that can help determine whether Lp(a) levels are causally involved in CHD. Large randomized trials of niacin in CHD prevention are already in progress (eg, HPS2-THRIVE [Heart Protection Study 2 Treatment of HDL (High-Density Lipoprotein) to Reduce the Incidence of Vascular Events]), although this agent raises high-density lipoprotein cholesterol levels and lowers lowdensity lipoprotein cholesterol and triglycerides in addition to lowering Lp(a) levels. 51 Studies of CHD that use specific LPA genetic variants as proxies for circulating Lp(a) levels should also reduce potential biases, but they may need to be very large. 50, 52, 53 The strengths and potential limitations of the present study merit careful consideration. These new data involve approximately 3 times as many incident CHD cases as the previous largest study 32 that quantitatively assessed Lp(a) levels. We identified participants in population registers, had high response and follow-up rates, used robust methods to ascertain CHD outcomes, and minimized potential biases by excluding individuals with prevalent CHD or stroke. Concomitant measurements of several established and emerging markers enabled direct comparisons of ORs with different markers and allowed adjustment for a range of possible confounding factors, although the latter was somewhat limited owing to a lack of data on low-and high-density lipoprotein cholesterol (but previously published studies have reported only weak associations of Lp[a] with these lipid subfractions [54] [55] [56] and little effect on ORs for CHD after adjustment for them 35, 39 ). The present Lp(a) assay involved a detection antibody directed toward the Apo(B-100) component of the Lp(a) particle, and, hence, the measurement of Lp(a) levels was not sensitive to Apo(a) isoforms. 25, 57 The validity of the assay was confirmed by the observation of high decade-todecade reproducibility in Lp(a) levels. However, because the present measurements did not provide specific information about Apo(a) isoforms (or record oxidized lowdensity lipoprotein), they could not test suggestions proposed in earlier studies of particularly strong associations with smaller-sized Lp(a) particles 58 or in the presence of markers of oxidative damage. 59 The present large-scale new data, reinforced by an updated meta-analysis of 31 longterm prospective studies, suggest only modest heterogeneity in OR for CHD with Lp(a) levels despite diversity of assay methods 23 and variability in Lp(a) levels across populations. Despite substantial differences noted in Lp(a) levels among studies, none of the factors recorded (eg, features related to blood handling, storage, or assay conditions) in this updated review yielded important differences in ORs (apart from the possibility of more extreme results in studies involving serum rather than plasma, an exploratory finding that requires further investigation). A more detailed exploration of potential sources of heterogeneity requires collaborative pooling of individual participant data from prospective studies. 60 Further studies are needed in racial groups, such as in people of African descent, in whom Lp(a) levels are particularly high. 61 In conclusion, we observed, under various circumstances, continuous associations between Lp(a) levels and CHD risk apparently independent of the effect of several established cardiovascular risk factors. Levels of Lp(a) are highly stable within individuals across many years and are only weakly correlated with known risk factors. Further assessment of their role in CHD prevention is warranted. ney Foundation of Canada, the Heart and Stroke Foundation of Canada, and the CIHR Institutes of Nutrition, Metabolism, and Diabetes and Circulatory and Respiratory Health. Dr Anderson holds the chair in Health Management Strategies at the University of Toronto. Role of the Sponsor: The study sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
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